Treatment with acyclovir of genital herpes simplex virus infection complicated by eczema herpeticum

G E ROBINSON,* G S UNDERHILL,† G E FORSTER,* C KENNEDY,* AND K McLEAN*
From the *Praed Street Clinic and the †Department of Virology, St Mary's Hospital, London

SUMMARY Eczema herpeticum is a potentially serious disease that may be fatal. We report two cases of infection with genital herpes simplex virus (HSV) that were complicated by eczema herpeticum and were treated successfully with acyclovir.

Introduction

Eczema herpeticum, or Kaposi's varicelliform eruption due to herpes simplex virus (HSV), is an uncommon but well recognised disease. The aetiological agent is usually HSV type I, but infection with HSV type II has been reported. People with atopic eczema are most frequently affected, but it has been associated less commonly with other skin disorders, such as Darier's disease, pemphigus, and seborrhoeic eczema. The disease ranges from a mild transient disorder to a fulminant and fatal illness. The mortality is probably less than 10%. Eczema herpeticum is characterised clinically by a sudden fever and the development of vesicles that appear in crops. The lesions are usually found in dermatitic skin but in severe cases normal skin is also affected. The vesicles enlarge peripherally, develop central umbilication, and progress through pustular and crusted phases. Secondary bacterial infection is common. Death may result from systemic dissemination of the virus, or may follow septicaemia, shock, and disseminated intravascular coagulation.

Attempts to treat eczema herpeticum with various agents have been reported. We report on two patients presenting with eczema herpeticum as a complication of first episode genital herpes who were treated with acyclovir.

Case reports

CASE 1
A 19 year old woman presented to this clinic with a seven day history of vulval soreness and ulceration.

CASE 2
A 25 year old man presented to this clinic with a six day history of genital ulceration. In the past month he had noted a worsening of eczema and had felt generally unwell. He had suffered from severe atopic eczema since childhood, treating himself with betamethasone cream intermittently. There was no history of previous herpetic infection. He had a regular female sexual partner who was asymptomatic.

On examination he had enlarged preauricular and inguinal lymph nodes but was not feverish. He had severe excoriated eczema and scarring and lichenification on his trunk, arms, and legs. Both eyelids were cracked, the left upper eyelid showing herpetic vesicles. There were extensive crusted herpetic lesions
affecting the shaft of the penis and the prepuce and extending into his groins.

Because he had severe eczema, genital herpes, and his left eyelid was affected he was admitted to hospital. He was treated with intravenous acyclovir (5 mg/kg) for 24 hours followed by oral acyclovir 200 mg five times daily for four days. Specimens from all lesions were cultured and HSV type I was isolated. An ophthalmic opinion was sought; the cornea was not affected, and 3% acyclovir ointment was prescribed for his left eye. After 24 hours' treatment he felt constitutionally better. No new lesions formed. Secondary infection of the genital lesions with Staphylococcus aureus was treated with oral flucloxacillin. When he was discharged from hospital the herpetic lesions were crusting, and one week later they had healed without scar formation.

Discussion

Kaposi's varicelliform eruption was first described in 1887.6 It may be described as a secondary viral infection, and is seen most frequently as a complication of atopic dermatitis and keratosis follicularis (Darier's disease). The principal causative virus is probably HSV, but vaccinia was responsible for a number of cases when vaccination against smallpox was routine.7 As 3% of the population have a history of atopic eczema and the reported incidence of genital HSV is increasing8 we expect the incidence of eczema herpeticum to rise. It is a potentially fatal condition and should therefore be treated aggressively to prevent the viscera being affected by viraemia and to control secondary bacterial infection.

Acyclovir is a potent antiviral agent that is effective against genital HSV in both intravenous9 and oral formulations by reducing viral shedding, the formation of new lesions, and pain. In our second patient it was administered intravenously to obtain maximum serum concentrations because the eye was threatened and the eczema herpeticum was severe. Both oral and intravenous formulations were effective in improving constitutional symptoms and healing lesions.

To our knowledge there are no published reports of genital infection with HSV complicated by eczema herpeticum having been treated with acyclovir. Although it is usually a complication of primary infection with HSV, eczema herpeticum does recur.1

We do not know if acyclovir would be effective in such recurrence.

We thank Drs J R W Harris and D Goldmeier for allowing us to review patients under their care.

References